Aktis Oncology, a Cambridge, Mass.-based biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers, closed a $72m Series A financing.
The company was founded and incubated by MPM Capital, which co-led the financing with EcoR1 Capital and Vida Ventures, with participation from Octagon Capital, TCG Crossover, Novartis and Bristol Myers Squibb.
Founded by Brian Goodman, PhD, Patrick Baeuerle, PhD, and Todd Foley, of MPM Capital and led by Matthew Roden, PhD, President and Chief Executive Officer, Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity. The company has developed proprietary platforms to discover tumor targeting agents designed with optimal pharmacology for delivering alpha radiotherapy.
Aktis Oncology plans to produce multiple development candidates with potential for efficacy against well-validated cancer targets.
The company is also led by:
- Paul Feldman, PhD, Chief Scientific Officer
- Brian Goodman, PhD, Head of Operations and Corporate Development
Aktis Oncology is headquartered in Cambridge, Mass. with laboratory operations in Research Triangle Park, NC.